Perrigo (PRGO) Competitors $22.26 -0.29 (-1.29%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$22.27 +0.01 (+0.04%) As of 09/12/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PRGO vs. JAZZ, CORT, SUPN, PCRX, NKTR, OMER, ASMB, CPIX, LLY, and JNJShould you be buying Perrigo stock or one of its competitors? The main competitors of Perrigo include Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceuticals" industry. Perrigo vs. Its Competitors Jazz Pharmaceuticals Corcept Therapeutics Supernus Pharmaceuticals Pacira BioSciences Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson Jazz Pharmaceuticals (NASDAQ:JAZZ) and Perrigo (NYSE:PRGO) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends. Do insiders & institutionals believe in JAZZ or PRGO? 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor JAZZ or PRGO? In the previous week, Jazz Pharmaceuticals had 3 more articles in the media than Perrigo. MarketBeat recorded 16 mentions for Jazz Pharmaceuticals and 13 mentions for Perrigo. Jazz Pharmaceuticals' average media sentiment score of 1.36 beat Perrigo's score of 1.29 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 12 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Perrigo 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, JAZZ or PRGO? Jazz Pharmaceuticals has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJazz Pharmaceuticals$4.07B1.88$560.12M-$6.73-18.75Perrigo$4.33B0.71-$171.80M-$0.58-38.38 Do analysts recommend JAZZ or PRGO? Jazz Pharmaceuticals presently has a consensus target price of $178.67, indicating a potential upside of 41.62%. Perrigo has a consensus target price of $33.00, indicating a potential upside of 48.25%. Given Perrigo's higher possible upside, analysts clearly believe Perrigo is more favorable than Jazz Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jazz Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.88Perrigo 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has more volatility & risk, JAZZ or PRGO? Jazz Pharmaceuticals has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Is JAZZ or PRGO more profitable? Perrigo has a net margin of -1.86% compared to Jazz Pharmaceuticals' net margin of -9.91%. Perrigo's return on equity of 9.09% beat Jazz Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Jazz Pharmaceuticals-9.91% 5.02% 1.73% Perrigo -1.86%9.09%3.96% SummaryJazz Pharmaceuticals and Perrigo tied by winning 8 of the 16 factors compared between the two stocks. Get Perrigo News Delivered to You Automatically Sign up to receive the latest news and ratings for PRGO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRGO vs. The Competition Export to ExcelMetricPerrigoMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$3.10B$10.83B$5.87B$21.69BDividend Yield5.24%1.83%5.68%3.47%P/E Ratio-38.3821.1374.5229.69Price / Sales0.7130.79548.3370.32Price / Cash4.4724.8137.5625.00Price / Book0.703.5212.164.58Net Income-$171.80M$210.50M$3.28B$1.00B7 Day Performance-1.73%-0.18%0.87%0.65%1 Month Performance-5.92%1.09%4.96%3.07%1 Year Performance-19.78%-10.96%60.74%14.34% Perrigo Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRGOPerrigo4.8986 of 5 stars$22.26-1.3%$33.00+48.2%-18.0%$3.10B$4.33B-38.388,379News CoveragePositive NewsJAZZJazz Pharmaceuticals4.5916 of 5 stars$127.75+1.3%$178.67+39.9%+18.5%$7.75B$4.07B-18.982,800Positive NewsCORTCorcept Therapeutics4.7741 of 5 stars$69.72+0.2%$134.50+92.9%+104.1%$7.35B$675.04M61.70300News CoverageAnalyst ForecastInsider TradeSUPNSupernus Pharmaceuticals2.5525 of 5 stars$45.12-0.6%$43.00-4.7%+47.1%$2.53B$661.82M39.23580Insider TradePCRXPacira BioSciences3.1791 of 5 stars$26.67-0.7%$30.83+15.6%+113.0%$1.20B$700.97M12.70720Positive NewsNKTRNektar Therapeutics4.0719 of 5 stars$29.86+1.8%$88.33+195.8%+159.6%$567.90M$98.43M-3.39220Insider TradeOMEROmeros3.9587 of 5 stars$4.16-1.7%$18.00+332.7%+11.0%$283.11MN/A-1.97210Positive NewsASMBAssembly Biosciences3.4503 of 5 stars$24.70-3.1%$38.67+56.5%+21.1%$189.51M$28.52M-4.43100News CoverageShort Interest ↑CPIXCumberland Pharmaceuticals1.0021 of 5 stars$3.49+0.6%N/A+164.6%$52.21M$37.87M-15.8680LLYEli Lilly and Company4.9979 of 5 stars$732.41+0.1%$950.17+29.7%-19.3%$693.36B$45.04B47.8747,000Trending NewsJNJJohnson & Johnson4.6864 of 5 stars$177.10+0.9%$176.29-0.5%+8.2%$426.69B$88.82B18.94138,100Trending NewsAnalyst UpgradeAnalyst Revision Related Companies and Tools Related Companies Jazz Pharmaceuticals Competitors Corcept Therapeutics Competitors Supernus Pharmaceuticals Competitors Pacira BioSciences Competitors Nektar Therapeutics Competitors Omeros Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Eli Lilly and Company Competitors Johnson & Johnson Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRGO) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perrigo Company plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Perrigo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
